Implications of NELFCD as A Drug Or Biomarker (G51497)

Target Name: NELFCD

NCBI ID: G51497

NELFCD

Implications of NELFCD as A Drug Or Biomarker

NELFCD (N-Acetyl-L-Leucine-5-Carboxylic Acid), also known as TH1L, is a protein that is expressed in a variety of tissues throughout the body, including the lungs, heart, kidneys, and intestines. It is a key regulator of cell signaling and has been implicated in a number of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

One of the key functions of NELFCD is its role in the regulation of immune cells, particularly T cells. T cells are a critical component of the immune system and play a key role in fighting off infections and cancer. NELFCD has been shown to regulate the activity of T cells, allowing them to divide and differentiate into functional immune cells.

In addition to its role in T cell regulation, NELFCD has also been shown to play a key role in the regulation of cell signaling. NELFCD has been shown to interact with a variety of signaling molecules, including TGF-β1, IL-2, and PDGF. These interactions allow NELFCD to regulate the activity of immune cells and influence the outcomes of a variety of biological processes.

The potential implications of NELFCD as a drug target or biomarker are significant. If NELFCD can be effectively targeted and inhibited, it may offer a new treatment option for a variety of diseases. For example, NELFCD has been shown to be involved in the development and progression of a variety of cancers, including breast, lung, and ovarian cancer. By inhibiting its activity, researchers may be able to develop new treatments for these cancers.

In addition to its potential as a cancer treatment, NELFCD has also been shown to be involved in the regulation of autoimmune disorders. autoimmune disorders are a leading cause of chronic disease and can cause a wide range of symptoms, including fatigue, joint pain, and skin rashes. NELFCD has been shown to play a key role in the regulation of autoimmune disorders, and may be a useful target for the development of new treatments for these disorders.

Another potential application of NELFCD is its use as a biomarker. NELFCD has been shown to be expressed in a variety of tissues and has been used as a biomarker for a number of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. By detecting the expression of NELFCD in these diseases, researchers may be able to develop new diagnostic tests and potentially identify earlier stages of disease.

Overall, NELFCD is a protein that has significant potential as a drug target or biomarker. Its role in the regulation of immune cells and cell signaling makes it an attractive target for the development of new treatments for a variety of diseases. Further research is needed to fully understand the implications of NELFCD and its potential as a drug or biomarker.

Protein Name: Negative Elongation Factor Complex Member C/D

Functions: Essential component of the NELF complex, a complex that negatively regulates the elongation of transcription by RNA polymerase II (PubMed:12612062). The NELF complex, which acts via an association with the DSIF complex and causes transcriptional pausing, is counteracted by the P-TEFb kinase complex (PubMed:10199401)

The "NELFCD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NELFCD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets